Fenbendazole (FEN) is an anthelmintic medicine that has been available since 1970 and was originally used to treat parasitic worm infestations. More recently, however, researchers have discovered that it is also effective against some types of cancers. In fact, it appears to be particularly effective against non-melanoma skin cancers and a type of lung cancer called NSCLC. It may even sensitize these tumours to radiotherapy.
Febendazole is well-tolerated by humans, and can be taken in capsule form. It is also an anti-parasitic medication, and is used to treat several parasitic infections in dogs, cats, horses, cattle, pigs, sheep and turkeys. It is also used to control neurocysticercosis in animals and can be administered orally, by injection or subcutaneously.
In a study performed in mice, fenbendazole was found to prevent tumor formation and suppress the growth of existing tumors. The results of the study suggest that fenbendazole might be useful in treating hepatocellular carcinoma, an extremely dangerous form of liver cancer which is usually fatal unless treated.
This particular cancer is caused by mutations in the p53 gene, and it has an unusual property: it can acquire resistance to many chemotherapy drugs over time. It is thought that this resistance is due to a genetic alteration of the cell that renders it incapable of responding to the drug, or that it becomes resistant to the drug by incorporating foreign material into its DNA. In either case, the resistance can render chemotherapy and other treatments useless.
Fenbendazole is an anti-parasitic medication that is thought to inhibit the synthesis of these proteins. It is believed to be able to interfere with the phosphorylation process in these cells, thereby stopping the cell from absorbing these chemicals. It is also able to block the growth of new blood vessels that would otherwise bring nutrients to a cancerous tumour, and it can even reduce the amount of oxygen in the tissue, which can cause the cells to die.
Unlike many other cancer treatments, fenbendazole has a very low degree of toxicity in humans. It is also relatively inexpensive to produce, which makes it a very viable treatment option for cancer patients.
A man named Joe Tippens survived his lung cancer thanks to fenbendazole, and developed the “Joe Tippens Cancer Protocol”. He suggests taking 222 mg per day of fenbendazole for three days consecutively, with four days off. This is a much lower dose than is normally recommended for human use, but it is an important starting point. The dosage can be increased as needed to obtain the best results. If you are considering this treatment, make sure to consult with your doctor first. Depending on the type of cancer you have, you may need a higher or lower dose. It is also a good idea to inform your doctor about any other medications you are taking, as some medications can interact with fenbendazole. fenbendazole 222mg capsules for humans